Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 8, 2022, the Board of Directors (the "Board") of Adhera
Therapeutics, Inc. (the "Company") appointed Zahed Subhan as the Company's Chief
Executive Officer and Andrew Kucharchuk as the Company's Chief Operating
Officer, effective September 30, 2022. Mr. Kucharchuk will continue to serve as
the Company's Chief Executive Officer until September 30, 2022.
Mr. Subhan, 64, has been serving as the Company's director since November 5,
2021. He has served as the Chief Executive Officer and director of Aestas Pharma
Inc. since 2015. Mr. Subhan has also been a director of Eppin Pharma Inc.
("Eppin") since 2013, and the Chief Executive Officer of Eppin from 2013 to
2018.
Mr. Kucharchuk, 41, has served as the Chariman of our Board and Chief Executive
Officer since July 7, 2020. He has also served on the Board of Directors of
Theralink Technologies, Inc. ("Theralink") since 2020 after previously serving
in such role from September 2015 to March 2017. Previously, he served as
President and Chief Financial Officer of Theralink from February 2016 until June
2020, as Chief Executive Officer of Theralink from November 2019 until June
2020, and as Chief Financial Officer of Theralink from 2009 to September 2015.
Mr. Kucharchuk has also served as Acting Chief Financial Officer of Theralink
from June 2020 to September 2020.
Item 7.01. Regulation FD Disclosure.
On September 8, 2022, the Board of the Company appointed Mr. Subhan as the
Company's Chairman of the Board.
© Edgar Online, source Glimpses
ADHERA THERAPEUTICS, INC. 
